Just off the heels of attending one of the biggest life sciences industry tradeshows, Interphex, and preparing for DIA and BIO, I wanted to share some tradeshow tips. By Rob Wright

Even with more than 8,800 employees and an annual budget of around $3.2 billion, the FDA’s task of protecting the public health seems daunting, considering the complexity of products being developed by industry. By Rob Wright

Layoffs are nothing new to the pharmaceutical industry. During my days in pharma, I went through re-alignments, restructurings, downsizing, right sizing, and layoffs about every 18 months. By Rob Wright

Allergan’s CEO, David Pyott, attributes some of the company’s success to securing a high proportion of  regulatory approvals around the globe due to  three things: Allergan’s business model, expertise through specialization, and attention to detail using the "flywheel effect." By Rob Wright

Pharmaceutical serialization could obtain a global standardization by learning from two different models which demonstrate a solution. By Rob Wright

Research by the University of Miami’s Touch Research Institute has revealed that human touch has wide-ranging physical and emotional benefits for people of all age groups.

The past month was a very busy one for all of us here at Life Science Leader. For me personally, in addition to writing two articles for this month’s magazine, I had the opportunity to attend five different meetings around the country. The first event I attended, Partnerships In Clinical Trials, was held in Orlando, FL, March 4 to 7.

Dr. Anita Goel, M.D., Ph.D., chairman and CEO for Nanobiosym, recently called me about her current project – integrating physics, biomedicine, and nanotechnology to accelerate the FDA approval process. By Rob Wright

This year’s R&D Leadership Summit took place March 19 to 20 in Aventura, FL. Organized by The Conference Forum and sponsored by RPS, the focus was on driving innovation, change, and performance of drug development and discovery. By  Rob Wright